2024-520449-21-00招募中2 期
Cemiplimab maintenance treatment for advanced adrenocortical cancer
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2025年6月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- To evaluate the effect of cemiplimab as a maintenance immunotherapy on PFS in patients with advanced ACC with no disease progression after 4–6 EDP-M cycles.
研究概览
简要总结
To evaluate the effect of cemiplimab as a maintenance immunotherapy on PFS in patients with advanced ACC with no disease progression after 4–6 EDP-M cycles.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Male and females >18 years of age
- •Willing and able to comply with clinic visits and study-related procedures.
- •Willing and able to provide informed consent signed by study patient or legally acceptable representative.
- •Able to understand and complete study-related questionnaires.
- •Patients with histologically confirmed ACC
- •Previous induction therapy with EDP-M followed by cytoreductive surgery if indicated
- •No disease progression after first line 4–6 EDP-M cycles
- •An ECOG PS of 0,1
- •Adequate organ and bone marrow function documented by: Hemoglobin >9.0 g/dL; ANC >1.5 x 10^9 /L; Platelet count >75 x 10^9 /L; Serum creatinine <1.5 ULN or estimated CrCl >30 mL/min; Adequate hepatic function: (Total bilirubin <1.5 x ULN; AST and ALT both <3 x ULN; ALP <2.5 x ULN)
- •Women of child-bearing potential (physiologically capable of becoming pregnant) that must agree to follow instructions for methods of contraception (including at least one highly effective contraception method, see study protocol) for the duration of treatment with study drug, and then for 6 months post treatment completion; must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug;
- •Women must not be breastfeeding.
- •Males that must agree to follow instructions for methods of contraception (see study protocol) for the duration of treatment with study drug, and then for a total of 6 months post treatment completion. In addition, male patients must not donate sperm for the time period specified above.
排除标准
- •History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 5 years.
- •Uncontrolled HIV, Hepatitis B or Hepatitis C (see protocol for details).
- •History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- •Active infection requiring systemic therapy.
- •Significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty / stenting / bypass grafting within the last 6 months OR CHF NYHA Class II-IV or history of CHF NYHA Class III or IV.
- •Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.
- •Patients with a history of solid organ transplant (exception: corneal transplant)
- •Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
- •ECOG PS ≥ 2
- •Pregnancy or breastfeeding.
- •Continued sexual activity in women of childbearing potential (physiologically capable of becoming pregnant) or sexually active men who are unwilling to practice highly effective contraception (including at least one highly effective contraception method, see study protocol) prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose.
- •History of active tuberculosis (TB, Bacillus Tuberculosis).
- •Untreated brain metastasis that may be considered active.
- •Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor.
- •Administration of a live vaccine within 30 days of the first dose of study treatment.
- •Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- •Diagnosis of immunodeficiency or systemic steroid therapy (i.e., dosing exceeding 10 mg of prednisone or equivalent). In case of mitotane treatment, a maximum steroid supplementation of 75 mg of cortone acetate (or equivalent hydrocortisone dose) will be accepted.
结局指标
主要结局
To evaluate the effect of cemiplimab as a maintenance immunotherapy on PFS in patients with advanced ACC with no disease progression after 4–6 EDP-M cycles.
To evaluate the effect of cemiplimab as a maintenance immunotherapy on PFS in patients with advanced ACC with no disease progression after 4–6 EDP-M cycles.
次要结局
- OS: time from the date of the study start to the date of death due to any cause.
- QoL: EORTC QLQ-C30 questionnaire.
- AEs and laboratory abnormalities as graded by NCI CTCAE v5.0.
研究者
Clinical Trial Center
Scientific
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activity to Adalimumab on first line with therapeutic drug concentration: A randomized, multicentre, controlled VEDIAN trial.Crohn's disease2023-508154-25-00Centre Hospitalier Universitaire De Saint Etienne220
招募中
3 期
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and Dexamethasone (VRd) in participants with Previously Untreated Multiple MyelomaMultiple Myeloma2023-506125-10-00European Myeloma Network Stichting, Emn Trial Office S.r.l. Impresa Sociale688
尚未招募
3 期
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal CancerNCT07277842Sun Yat-sen University382
招募中
2 期
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line TherapyNCT07309185Shandong Tumor Hospital66
招募中
2 期
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)2024-512652-38-00Replimune Group Inc.143